Ferring Pharmaceuticals is a mid-size pharma headquartered in CH. The company currently has 20 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
1
Active Trials
20
Top Modality
N/A
Focus Area
Solid Tumors
Therapeutic areas and modalities where Ferring Pharmaceuticals is most active based on deal history and clinical trial data.
Key indicators of Ferring Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Acquisition Appetite
Strategic Priorities
Ferring Pharmaceuticals has 20 active clinical trials across 5 development phases.
6
Unknown
3
Not Applicable
2
Phase 1
6
Phase 2
3
Phase 3
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Ferring Pharmaceuticals is a mid-size pharma company based in CH that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Ferring Pharmaceuticals include Solid Tumors (10 deals and trials), Cardiovascular (1 deal and trial), and Metabolic (1 deal and trial).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ferring Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Ferring Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.
© 2026 Ambrosia Ventures. All rights reserved.
Benchmarks powered by 1,900+ real biopharma licensing deals